Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer
Cytek Aurora™ Evo
FREMONT, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- In a move that underscores its dedication to shaping the future of cell analysis, Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the launch of the Cytek Aurora™ Evo system, a new full spectrum flow cytometer that improves on its flagship Cytek Aurora system.
First launched in 2017 to address the limitations of existing flow cytometry technologies, Cytek's Full Spectrum Profiling™ (FSP®) systems have become the spectral technology of choice for researchers worldwide, with over 2,600 peer-reviewed publications citing its use – more than any other spectral flow cytometer.
Building on this groundbreaking success, the new Cytek Aurora Evo system has been reengineered to carry forward the proven reliability and reproducibility of the Cytek Aurora system, while introducing high-throughput and automation capabilities to meet the demands of modern research. The Cytek Aurora Evo system utilizes Cytek's FSP technology, continuing to provide the field-tested capability to run large multicolor experiments without compromising data quality, as well as an unparalleled level of assay flexibility. The ability to resolve both small particles and large cells on a single instrument allows scientists to tackle a wider range of applications with confidence. The newly added capabilities of improved sample throughput, automated instrument maintenance, and data harmonization were all added to empower researchers to accelerate discoveries with greater speed and confidence.
With increasing demand for high-performance, flexible, and efficient cell analysis tools, the new Cytek Aurora Evo flow cytometer is well-positioned to meet the evolving needs of researchers and further drive the adoption of spectral flow cytometry. Key features and benefits of the new system include:
Instrument Standardization: Harmonized instruments allow for consistent, accurate and reproducible biological data across systems, labs and time.
High-Resolution and Throughput: A unique optical and electronics design enables excellent sensitivity and resolution across flow rates, from low (15 µL/min) to max (200 µL/min). Samples can now be acquired 2x faster than before.
Small Particle Detection: Previously available as an optional upgrade on the Cytek Aurora system, this capability is now built into the new Cytek Aurora Evo flow cytometer, enabling researchers to detect and resolve extracellular vesicles, viruses, bacteria and other nanoparticles.
Automation Capabilities: Minimize instrument maintenance and maximize efficiency. An integrated plate loader supports multiple carrier types, offering flexible user modes for both low carryover and high-throughput needs. Automated startup and shutdown further streamline workflows, reducing downtime while ensuring high-quality, high-resolution data.
Recognized as a pioneer in spectral flow cytometry, Cytek's distinctive approach is renowned for its profound influence on advancing the understanding of cell biology, immunology, oncology and targeted therapeutic methodologies. 'Cytek's Aurora and Northern Lights™ systems have helped revolutionize immunology research and single-cell analysis,' said Ming Yan, Ph.D., CTO of Cytek Biosciences. 'Over the years, we have continuously pushed the boundaries of what's possible in spectral flow cytometry. With this latest launch of the Cytek Aurora Evo system, we've integrated these advancements into a powerful, high-throughput workhorse that delivers an unmatched combination of performance, reliability, efficiency and ease of use – enabling more scientists to leverage the full potential of spectral flow cytometry.'
The Cytek Aurora Evo system will make its public debut at CYTO 2025, with demonstrations taking place in Cytek's booth.
For more information, please visit https://cytekbio.com/pages/aurora-evo.
About Cytek Biosciences, Inc.Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
Cytek's products are for research use only and not for use in diagnostic procedures (other than Cytek's Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis, Guava and Muse are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek's website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. These forward-looking statements include statements regarding Cytek's business strategies, product plans and expectations, and market opportunities. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include global geopolitical, economic and market conditions; Cytek's ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek's ability to evaluate its prospects for future viability and predict future performance; Cytek's ability to accurately forecast customer demand and adoption of its products; Cytek's ability to recognize the anticipated benefits of collaborations; Cytek's dependence on certain sole and single source suppliers; competition; market acceptance of Cytek's current and potential products; Cytek's ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek's ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek's ability to increase penetration in its existing markets and expand into adjacent markets; Cytek's ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek's ability to successfully develop and introduce new products; Cytek's ability to maintain, protect and enhance its intellectual property; Cytek's ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section entitled 'Risk Factors' set forth in Cytek's Quarterly Report on Form 10-Q filed on May 8, 2025 with the SEC, and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek's forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the events and circumstances reflected in the forward-looking statements will occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek's as of any date subsequent to the date of this press release.
Media Contact:Stephanie OlsenLages & Associates(949) 453-8080stephanie@lages.com
Investor Contact:Paul GoodsonHead of Investor RelationsCytek Biosciencespgoodson@cytekbio.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/10555422-5eb8-4261-8b5a-d3b296ad100bSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
17 minutes ago
- Yahoo
AAPL Stock Price Prediction: Where Apple Could Be by 2025, 2026, and 2030
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Analysts are saying that Apple could hit $410 by 2030. Bullish on AAPL? Invest in Apple on SoFi with no commissions. If it's your first time signing up for SoFi, you'll receive up to $1,000 in stock when you first fund your account. Plus, get a 1% bonus if you transfer your investments and keep them there until December 31, 2025. Apple Inc (NASDAQ:AAPL) remains one of the world's most influential and closely tracked tech stocks. Its massive installed base, iconic products, and fast-growing Services business make it a focal point for both growth and value investors. As of August 2025, Apple's share price is hovering near all-time highs as investors weigh the company's future earnings power in artificial intelligence (AI), wearables, and digital services. Below, we'll take a close look at how Apple stock is performing today, where its valuation stands, and what experts think could happen to its price in 2025, 2026, and 2030. You'll find projections from Wall Street analysts and independent models, along with an overview of the key trends, possible risks, and different opinions shaping Apple's future. Current Apple Stock Overview Market Cap: $3.25 trillion Trailing P/E Ratio: 32.36 Forward P/E Ratio: 26.95 1-Year Return: +1.86% 2025 Year to Date: Down roughly 15%, but rebounding strongly from earlier lows As of August 2025, Apple (AAPL) trades near $224 per share, recovering from a steep first-half drop of over 15% as investor sentiment improves. The stock's trailing P/E ratio of 32.36 sits well above its long-term average in the low-to-mid 20s, reflecting the market's continued premium on Apple's brand and earnings power. Over the past year, shares have inched up about 1.9%, showcasing the company's historical resilience and ability to rebound from downturns. This elevated valuation suggests investors expect steady profit growth despite competitive pressures and rapid tech sector changes. With high margins and recurring revenue, Apple's Services division (App Store, Apple Music, iCloud, and more) is now the company's growth engine. iPhone demand, especially in China and India, remains a central driver, with an anticipated surge for the iPhone 17 launch in the third quarter of 2025. AI has been called an 'elephant in the room.' Apple's monetization strategy there has yet to emerge, with Wall Street still waiting for significant generative AI products. Competitive and regulatory headwinds are increasing, but Apple's pricing power and sticky ecosystem underpin optimism for the long-term. Don't Miss: The same firms that backed Uber, Venmo and eBay are investing in this pre-IPO company disrupting a $1.8T market — and you can too at just $2.90/share. Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." Here's how you can earn passive income with just $100. Wall Street sentiment toward Apple (AAPL) is broadly positive. According to Benzinga, 29 analysts cover the stock, with a consensus price target of $233.04, ranging from a high of $300 (Tigress Financial) to a low of $160 (HSBC). The three most recent ratings from Wedbush, B of A Securities, and DA Davidson average $256.67, implying about 12.7% upside from current levels. This reflects optimism about Apple's long-term growth despite ongoing debates over its innovation pace and competitive pressures. Quick Snapshot Table of PredictionsYear Lowest Prediction Average Prediction Maximum Prediction 2025 $170 $225 $300 2026 $218 $362 $411 2027 $245 $362 $420 2028 $290 $387 $470 2029 $320 $412 $495 2030 $287 $349 $410 The forecast range in this table is based on algorithmic projections provided by Coin Price Forecast, StockScan, CoinCodex, and Market Beat. These models use historical price trends, volatility patterns, and moving averages to estimate future stock prices over multiple time horizons. Bull & Bear Case Before making a decision on Apple stock, it's crucial to weigh both the optimistic arguments for continued growth and the potential headwinds that could limit future returns. Bull Case Growth from iPhone replacement cycle (iPhone 17 and beyond), surging Services segment, and potential upside from new AI features or augmented reality/virtual reality (AR/VR) launches. High-margin services and wearables provide recurring revenue and ecosystem lock-in. Most analysts maintain "Buy" or "Moderate Buy" ratings for AAPL, citing balance sheet strength, buybacks, and innovation pipeline. Bear Case Regulatory and antitrust scrutiny in the U.S. and Europe could limit the percentage Apple collects from App Store sales or hamper new services. Margins pressured as hardware growth slows, especially given Chinese competition/risk of supply chain disruptions. Apple's current valuation remains rich unless earnings growth accelerates; any disappointment could prompt a sharp downside given macro risks. Despite Apple's massive resources, the company faces persistent criticism for lagging behind peers like Microsoft, Google, and even Meta in the rollout of advanced generative AI features. Apple Stock Price Prediction for 2025 Forecast Range: $170–$300 Analysts see moderate upside from today's price of around $224, with bulls eyeing further gains into late 2025 should the iPhone cycle and services outpace current estimates. A key risk is that valuation multiples could compress if revenue trends don't reaccelerate. Competitive gains from rivals and global regulation remain overhangs. Apple Stock Price Prediction for 2026 Forecast Range: $218–$411 2026 targets diverge, with some models projecting steady, earnings-driven creep, while others foresee strong upside from new platform adoption (AI, wearables). Bullish scenarios anticipate 60% to 80% upside if innovation cycles hit. Apple Stock Price Prediction for 2030 Forecast Range: $287–$478 A balanced CAGR model (8% to 12% annualized) from today suggests AAPL could close 2030 between $350 and $415. Structural upside exists if new categories (AR glasses) scale successfully. Downside risks are disruption to Apple's ecosystem, regulatory interventions, or margin erosion as competition heats up. Investment Considerations Apple remains a core blue chip, suitable for long-term growth investors, tech believers, and dividend reinvestors. Its record of buybacks, dividend hikes, and world-class brand equity keeps institutional and retail holders committed. As of mid-2025, hedge funds and pensions maintain overweight exposure, betting on Apple's proven playbook of ecosystem expansion and cash generation. Key risks: macroeconomic swings, intensified tech competition (especially in China), global regulatory action, and elevated earnings multiple. Upcoming catalysts to watch include Q3 earnings (iPhone 17 launch), Services segment margin growth, and the debut of new AI-powered features. Diversified investors should monitor Apple's valuation multiples and sector positioning. Significant drawdowns are possible if revenue growth disappoints or global tech sentiment sours. See Next: 'Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can invest today for just $0.30/share. This article AAPL Stock Price Prediction: Where Apple Could Be by 2025, 2026, and 2030 originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Thinking of Buying Tesla Stock? Here Are 2 Red Flags to Watch
Key Points Tesla's heavy reliance on Elon Musk adds significant leadership risk. Increasing competition from established automakers and Chinese EV makers is pressuring Tesla's dominance. Investors need to be comfortable with Tesla's high valuation. These 10 stocks could mint the next wave of millionaires › Tesla (NASDAQ: TSLA) has long been the front runner in the electric vehicle (EV) revolution in the U.S. Its innovation, brand strength, and rapid growth have made it a favorite among investors. Yet, despite its impressive track record, there are two big risks that investors should carefully consider before buying Tesla stock today. 1. The Elon Musk factor Elon Musk's leadership is often cited as Tesla's greatest strength -- and, paradoxically, one of its most significant vulnerabilities. Musk's vision and hands-on approach have driven Tesla's technological breakthroughs and ambitious expansion. However, this heavy reliance on a single individual introduces what investors refer to as "key man risk." If Musk were to step back from daily operations or shift his focus to other projects, Tesla might face challenges in maintaining its momentum. Though Tesla's management team has grown stronger, few executives command the same vision, drive, and public attention as Musk. Recently, Musk's increasing involvement in political activities has raised concerns about potential distractions or reputational risks for Tesla. While the company has remained operationally strong, these developments underscore the uncertainty around its future leadership continuity. While Tesla's success lies not only with Musk but also with his team, which has executed well on his vision -- no one can build a trillion-dollar company alone -- there is still no clear successor (or a viable management team) . The silver lining here is that the Tesla board has become more serious about finding one in recent months, largely due to the CEO's active involvement in politics. For investors, this means that Tesla's fortunes remain closely tied to Musk's presence and decisions -- a factor that adds a layer of risk to the investment. 2. Intensifying competition Tesla might have been an early mover in the EV industry, but its dominance is no longer guaranteed. The industry landscape is rapidly evolving, with legacy automakers and new entrants accelerating their electric ambitions. Companies like Ford and General Motors are aggressively expanding their EV lineups. For instance, Ford plans to introduce a $30,000 midsize truck by 2027. That price is significantly lower than the average for an EV, and Ford is investing $5 billion in its EV production to make it happen. GM, on the other hand, is working hard on next-generation battery technologies to improve range, charging performance, and cost. Meanwhile, Chinese manufacturers such as BYD are growing their international footprints, particularly in Europe, where Tesla experienced a nearly 27% sales declinein July 2025. BYD's battery technology, government support, and competitive pricing make it a formidable challenger. In addition, a host of EV start-ups are innovating in battery tech, autonomous driving, and new business models, further intensifying competition. While Tesla is not sitting still -- it is working on becoming the lowest-cost producer by cutting prices to grow sales volume and achieve economies of scale -- there is no guarantee that it can maintain its market share over time. In short, it's no longer the only player in town. What does this mean for investors? Tesla's story remains compelling: It's a pioneer with a powerful brand, innovative products, and potential optionality with some of its long shot bets (robotaxi, humanoid robots, etc). But the key man risk surrounding Musk and the escalating competitive landscape are real concerns that investors can't ignore. If Tesla continues to innovate more rapidly than its rivals, the company could sustain its growth trajectory. However, any leadership changes or slips in market position could hurt the business and its share price. While these two risks don't necessarily call for the sale of the stock, they do mean that investors should think carefully before buying the stock today. Tesla stock trades at a significant premium valuation to other carmakers. For perspective, Tesla has a price-to-sales (P/S) ratio of 12.9, compared to GM's 0.3. Unless you're comfortable with the risks and the high valuation, buying the stock today may not be a prudent decision. Don't miss this second chance at a potentially lucrative opportunity Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $467,985!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $44,015!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $668,155!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of August 13, 2025 Lawrence Nga has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla. The Motley Fool recommends BYD Company and General Motors. The Motley Fool has a disclosure policy. Thinking of Buying Tesla Stock? Here Are 2 Red Flags to Watch was originally published by The Motley Fool
